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Abstract Cardiomyocytes (CMs) derived from induced plurip-
otent stem cells (iPSCs) hold great promise for patient-specific
disease modeling, drug screening and cell therapy. However,
existing protocols for CM differentiation of iPSCs besides being
highly dependent on the application of expensive growth factors
show low reproducibility and scalability. The aim of this work
was to develop a robust and scalable strategy formass production
of iPSC-derived CMs by designing a bioreactor protocol that
ensures a hypoxic and mechanical environment. Murine iPSCs
were cultivated as aggregates in either stirred tank or WAVE
bioreactors. The effect of dissolved oxygen and mechanical
forces, promoted by different hydrodynamic environments, on
CM differentiation was evaluated. Combining a hypoxia culture
(4 % O2 tension) with an intermittent agitation profile in stirred
tank bioreactors resulted in an improvement of about 1000-fold
in CMyieldswhen compared to normoxic (20%O2 tension) and
continuously agitated cultures. Additionally, we showed for the
first time that wave-induced agitation enables the differentiation
of iPSCs towards CMs at faster kinetics and with higher yields
(60 CMs/input iPSC). In an 11-day differentiation protocol,
clinically relevant numbers of CMs (2.3×109 CMs/1 L) were
produced, and CMs exhibited typical cardiac sarcomeric struc-
tures, calcium transients, electrophysiological profiles and drug
responsiveness. This work describes significant advances to-
wards scalable cardiomyocyte differentiation of murine iPSC,
paving the way for the implementation of this strategy for mass
production of their human counterparts and their use for cardiac
repair and cardiovascular research.
Keywords Induced pluripotent stem cells . Cardiomyocyte
differentiation . Hypoxia . Mechanical environment .
Bioreactor hydrodynamics .Mass production
Introduction
The inability of mature cardiomyocytes (CMs) to proliferate
leads to a permanent loss of functional cells after injury [1].
Previous studies in animal models of myocardial infarction
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have demonstrated that the function of a damaged heart may
be improved by transplantation of sufficient numbers of func-
tional CMs [2]. Over the last years, pluripotent stem cells
(PSCs), including embryonic stem cells (ESCs) and induced
pluripotent stem cells (iPSCs), have emerged as an attractive
candidate stem cell source for obtaining CMs [3, 4]. The
inherent capacity to grow indefinitely and to differentiate into
all mature cells of the human body make PSCs the only cell
source that can provide ex-vivo an unlimited number of func-
tional and potentially autologous CMs for transplantation. The
clinical translation of human ESC-derivatives has been greatly
hampered by the risk of immune rejection due to their
allogenicity and by ethical concerns [5]. iPSCs can circum-
vent these drawbacks, allowing for ethically “acceptable” and
safe patient-specific therapies [6, 7]. Moreover, iPSCs consti-
tute a promising tool to establish disease-specific models of
human inherited cardiac disorders and platforms for drug
discovery and toxicity testing [7, 8].
In the last 5 years, several methodologies have been de-
scribed for the differentiation of murine [9–12] and human
[13–18] iPSCs into functional CMs based on the knowledge
acquired in previous studies with ESCs. Still, several chal-
lenges remain that currently preclude their widespread appli-
cation. Those protocols typically involve a complex stage-
specific application of exogenous growth factors which are
costly, degrade rapidly, do not readily diffuse into complex 3D
aggregates and exhibit lot-to-lot variation in their bioactivity
[19]. Moreover, despite recent improvements in cardiac dif-
ferentiation protocols [15–18] these are still associated with
low reproducibility and scalability [5], being unsuitable to
provide the large numbers of CMs needed to exert functional
benefit after a heart attack (about 1–2×109 CMs per patient)
[20]. Therefore, robust and scalable bioprocesses for CM
production less dependent on the use of inductive factors are
required for a faster transition of iPSCs to the clinical and
industrial fields.
One of the most powerful strategies for scaling-up the
production of iPSC derivatives consists in cultivating the cells
as 3D cell aggregates called embryoid bodies in bioreactor
systems that continuously assure monitoring and control of
the environmental conditions (pH, pO2 and agitation profile)
[21, 22]. A close control of the physical environment was
shown to be essential for guiding cell fate decisions through
expansion and differentiation routes. Low oxygen tensions
(2–5 % O2) have been shown to enhance the proliferation of
PSCs [22–24] and their differentiation to CMs [25–27]. In-
deed, it is well known that cells in the early developing
embryo are exposed to low oxygen levels. In hamsters and
rabbits, for example, intrauterine oxygen concentrations de-
crease during blastulation and implantation to 5.3 % O2 and
3.5 % O2, respectively [28]. Thus, lowering the oxygen con-
centration from normoxic atmospheric levels (20 % O2) to
more physiological levels (2–5 % O2 or atmospheric hypoxia)
might be beneficial in PSC cultures due to the importance of
this environmental condition during embryonic development.
Mechanical cues from the environment are also translated
into biological signals that mediate cell structure, survival,
migration, proliferation, and differentiation [29, 30]. Several
studies have provided evidence that applied mechanical forces
including cyclic strain and stretch, fluid shear stress and
hydrostatic compression modulate differentiation of cells that
reside in mechanically dynamic environments, such as CMs
[31–33], vascular smooth muscle cells [34], endothelial cells
[35] and chondrocytes [36]. In particular, CMs are continu-
ously subjected to cyclic mechanical strains promoted by the
rhythmic heart beating [37]. CM-enriched tissue constructs
are often subjected to cyclic tensions to increase their force of
contraction, facilitate organization of cellular structures and
consequently improve their cardiac function in vivo [38].
Thus, the hypothesis that mechanical loading promotes
cardiomyogenesis of PSCs has started to be explored [31,
39, 40]. It was recently reported that ESCs cultured on elastic
polymer [poly (lactide-co-caprolactone), PLCL] scaffolds and
subjected to 1 % cyclic uniaxial stretch, in a custom-made
strain device, demonstrated commitment towards CM lineage
as noted by an increased cardiac gene expression compared to
unstrained controls [31]. Nevertheless, the low high-
throughput design and scalability of these devices, custom
built to apply mechanical strains, makes them unsuitable to
generate large numbers of cells on a therapeutically relevant
scale.
In the present work we focused on the development of
robust, scalable and integrated platforms for iPSC-derived
CM production and purification using bioreactor systems with
automated process control, including online measurement and
adjustment of the culture parameters. Our strategy consisted
on modulating key environmental parameters for efficient and
reliable differentiation of iPSC towards the CM lineage, re-
ducing the need of using inductive factors. We explored the
impact of dissolved oxygen (DO) and mechanical forces on
CM differentiation of iPSCs by using two distinct bioreactor
systems, namely stirred tank and WAVE bioreactors. We
applied mechanical forces to cells by manipulating the hydro-
dynamic environment, more specifically the type and profile
of agitation. We describe for the first time a protocol for
efficient mass production of functional CMs derived from
murine iPSCs that combines a hypoxic environment with an
intermittent stirring or a wave-induced agitation profile.
Methods
iPSC Culture on Feeder Layers
A murine transgenic αPIG-iPS cell line, in which the
puromycin-N-acetyl transferase and the enhanced green
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fluorescent protein (eGFP) genes are under the control of the
cardiac-specific alpha-myosin heavy chain (α-MHC) promot-
er [41], was used in this study to facilitate bioprocess devel-
opment. The fluorescence marker and the antibiotic resistance
genes, specifically expressed in CMs, allow easy monitoring
of the cardiac differentiation process and selection of a highly
pure CM population upon addition of puromycin into the
media, respectively. iPSCs were cultivated on a monolayer
of mitotically inactivated murine embryonic fibroblasts
(MEFs) in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 15 % (v/v) fetal bovine serum (FBS),
1 % (v/v) non-essential amino acids (NEAA), 2 mM L-
glutamine, 50 μM β-mercaptoethanol, 500 μg/mL neomycin
sulfate (all from Invitrogen, UK), and 1000 U/mL leukemia
inhibitory factor (LIF) (ESGRO, Merck Millipore, Germany),
at 37ºC in a humidified atmosphere of 5 % CO2. Cells were
passaged every two days as previously reported [41].
iPSC Differentiation in Stirred Tank Bioreactors
To promote cell aggregation 0.7×105 cell/mL were inoculated
into plastic Erlenmeyer flasks (Corning, USA) containing
100 mL of differentiation medium (Iscove’s modified
Dulbecco’s medium (IMDM) with GlutaMAX, supplemented
with 20 % (v/v) FBS, 1×NEAA, 1 % (v/v) Pen/Strep, 50 μM
β-mercaptoethanol (all from Invitrogen, UK) and 100 μM
ascorbic acid (Wako, Germany), and incubated at 37ºC in a
5 % CO2 humidified atmosphere on an orbital shaker at 80–
90 rpm. After two days aggregates were transferred into
stirred tank bioreactors (DasGip cellferm-pro bioreactor sys-
tem, Germany) and cultured at a concentration of 150
aggregates/mL in 200 mL of differentiation medium. Medium
was partially changed at days 9 (50 % v/v), 12 (70 % v/v) and
14 (50 % v/v) by selection medium (differentiation media
without ascorbic acid supplemented with puromycin at a final
concentration of 8 μg/mL (InvivoGen, USA)) to eliminate
non-CMs and promote CM selection. Antibiotic treatment
resulted in the generation of pure aggregates of CMs (desig-
nated hereafter as cardiospheres). The experimental set up is
illustrated in Fig. 1. All cultures were performed in computer-
controlled stirred tank bioreactors equipped with a trapezoid
shaped paddle impeller with arms and operated under defined
conditions (CO2: 5 %; temperature: 37 °C; DO: 20 % O2
tension (atmospheric normoxia) or 4 % O2 tension (atmo-
spheric hypoxia); surface aeration rate: 0.1 vvm (gas volume
flow per unit of liquid volume per minute); agitation rate:
90 rpm for complete continuous stirred-tank reactor (CSTR)
behavior; agitation profile: continuous or intermittent (ON:
30 s, OFF: 0 s) with or without direction change; cyclic
mechanical frequency (defined by the number of stirring
interruptions per unit of time): 0.033Hz). Data acquisition
and process control were performed using DasGip Control
Software 4.0. Three independent bioreactor runs were per-
formed for every experimental setting.
iPSC Differentiation in WAVE Bioreactors
Cell aggregation was promoted in CellbagTM—WAVE
bioreactors (GE Healthcare, Sweden) for 2 days (Fig. 1).
Briefly, 0.7×105 cell/mL were inoculated as single cells
into WAVE bioreactors containing 500 mL of differentia-
tion medium. At day 2, aggregate concentration was ad-
justed to 150 aggregates/mL by increasing the working
volume to 1 L. At day 9 of differentiation, CM purifica-
tion was initiated by exchanging half of the culture media
with selection medium. Aggregates were cultivated for
additional 2 days in these conditions. The experimental
set up is shown in Fig. 1. All cultures were performed in
computer-controlled WAVE bioreactor systems under de-
fined conditions (CO2: 5 %; temperature: 37 °C; DO: 4 %
O2 tension; surface aeration rate: 0.1 vvm; rocking angle:
4; rocking rate (adjusted throughout culture time accord-
ing to the aggregate size): 10 rocks/min (day0–day1), 12
rocks/min (day1–day2), 25 rocks/min (day2–day7), 26
rocks/min (day7–day11); cyclic mechanical frequency
from day 2 to day 11 (defined by the change in wave
motion per unit of time): 0.82 to 0.86 Hz). Data acquisi-
tion and process control were performed using UNI-
CORN* DAQ 1.0 software. Three independent bioreactor
runs were performed for every experimental setting.
Dissociation of Cardiospheres
At the end of the differentiation process, cardiospheres were
harvested from the bioreactor, dissociated to single cells by
incubation with 0.25 % (w/v) Trypsin-EDTA (Invitrogen,
UK) for 5–7 min at 37 °C and transferred to CELLstart™
(Invitrogen, UK) coated 6- or 24-well plates for further
characterization.
Methods for evaluation of cell and aggregate concentration,
monitorization of CM differentiation and characterization of
iPSC-derived CMs are provided in the supplementary data
supplement.
Results
Effect of Dissolved Oxygen on CM Differentiation of iPSCs
in Stirred Tank Bioreactors
In order to establish a robust and scalable platform for pro-
duction of functional iPSC-derived CMs, we first investigated
the effect of DO on cardiac iPSC differentiation in stirred tank
bioreactor systems. For that purpose, we compared the effect
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of normoxic atmospheric oxygen levels (20 % O2 tension)
with physiological oxygen levels (2–5 % O2 tension or atmo-
spheric hypoxia). Within this range of physiological oxygen
levels, we selected a value of 4%O2 since previously reported
studies showed that this oxygen concentration improves CM
differentiation in ESC aggregate cultures [25, 26].
Aggregation of single cell suspension was promoted in
Erlenmeyers and orbital agitation for 48 h under normoxia
conditions; these conditions resulted in the formation of small
aggregates with a mean size of 155±56 μm that readily
metabolized the vital dye fluorescein diacetate but not the
dead cell marker propidium iodide (Supplementary Fig. I).
These aggregates were transferred to fully controlled stirred
tank bioreactors and cultured under either normoxic (DO=
20 % O2) or hypoxic (DO=4 % O2) conditions for additional
14 days (Fig. 1).
The results showed that a DO of 4 % O2 maximizes
cell proliferation and CM differentiation (Fig. 2). In these
culture conditions, the size of aggregates, the total number
of cells and aggregates were higher throughout the culture
(Fig. 2a–c) resulting in a significantly higher expansion
fold on day 9 of differentiation when compared to
normoxic conditions (44.9±2.7 versus 12.2±1.4 cells/
initial iPSC, p=0.001, Table 1). Moreover, first eGFP-
positive cells and contracting areas in aggregates cultured
under hypoxia were observed already on day 7 of differ-
entiation, contrasting with cell aggregates cultured at
20 % O2 where eGFP-positive cells and beating areas
were rarely observed throughout culture time (Fig. 2a).
The higher overall cell expansion in hypoxic cultures
corresponded to a significant improvement in CM yield
as determined on day 16 of differentiation, after 7 days of
Fig. 1 Experimental scheme for differentiation and purification of iPSC-
derived CMs in stirred tank and WAVE bioreactors. In stirred tank
bioreactors, an aggregation step was first performed in an Erlenmeyer
for 48 h. After this time, aggregates were transferred to bioreactors to
yield 150 aggregates/mL and cultured in the presence of ascorbic acid for
additional 7 days. At day 9, puromycin was added to the medium to
eliminate non-CMs. After 7 days of antibiotic-based CM selection, pure
CM aggregates (cardiospheres) were harvested, dissociated and CMs
were cul tured in 2D plates for character izat ion studies
(immunofluorescence microscopy and electrophysiological studies). In
WAVE bioreactor cultures, cells were inoculated as single cells directly
into theWAVE bioreactor and at day 2 the culture volume was adjusted to
obtain 150 aggregates/mL. Aggregates were cultured in the presence of
ascorbic acid for additional 7 days. At day 9, CM lineage selection was
initiated and lasted 2 days. At day 11, aggregates were harvested, disso-
ciated and plated in 2D plates for further characterization. Culture condi-
tions evaluated in each bioreactor system are depicted in the bottom of the
schematic workflow
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puromycin selection (11.3±3.7 vs. 0.05±0.02 CMs/input
iPSC, p=0.045, Fig. 2d), and to an approximately 210-
fold enhancement in CM numbers compared to normoxia
(33.6±7.6×106 CMs vs. 0.15±0.06×106 CMs per biore-
actor run, p=0.01, Fig. 2d). Since a low DO environment
proved to be a key parameter in enhancing CM
Fig. 2 Effect of DO on CM differentiation of iPSCs in stirred tank
bioreactors. Aggregates were inoculated at day 2 in stirred tank bioreac-
tors at DO of 20 % O2 (atmospheric normoxia) or 4 % O2 (atmospheric
hypoxia). a. Merged phase contrast and fluorescence images showing cell
aggregates composed by eGFP-positive cells (green) at days 7, 9 and 16
of culture. Scale bars: 200 μm. b. Profile of total cell number during
culture time. c. Total number of aggregates at days 2, 4, 9 and 16. The
number of eGFP-positive aggregates is indicated by striped bars. d. Total
number of CMs produced per bioreactor run (black bars) and CM yield
(number of CMs at day 16/input iPSC, striped bars) obtained in both
normoxic and hypoxic culture conditions. Error bars (b–d) represent SD
of 3 individual bioreactor experiments. Significantly different, P<0.05
(*) and P<0.01 (**)
Table 1 Quantitative characterization of CM differentiation of iPSC in automated stirred tank and WAVE bioreactors
Culture system Stirred tank bioreactor WAVE bioreactor

















Expansion fold (cells on day 9/input iPSC) 44.9±2.7 23.7±1.7 73.4±7.6 65.7±7.2
CM purity before purification (day 9, %eGFP-positive cells) 23.3±5.0 16.5±3.7 43.9±6.6 76.0±5.8
CM purity after selection (day 16/11, %eGFP-positive cells) 85.7±4.1 77.0±3.0 97.4±0.4 97.6±1.0
Final CM number (×106 CMs) 33.6±7.6 19.5±1.7 128.1±3.3 2279.8±69.2
Final CM yield (number of CMs/input iPSC) 11.3±3.7 6.8±1.1 44.0±2.1 60.8±0.7
Final CM number per liter of culture medium throughput (×106 CMs/L) 78.1±11.8 45.4±4.0 295.9±8.8 1561.1±87.3
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differentiation of iPSCs, we selected this culture condition
to be used in further experiments.
Impact of Agitation Profile on CM Differentiation of iPSC
in Stirred Tank Bioreactors
The effect of different agitation profiles on CM differentiation
was assessed using stirred tank bioreactors operating under
hypoxic conditions. A continuous agitation was compared
with an intermittent agitation with and without change in the
agitation direction. Based on previous reports that mechanical
stimulation enhances contractile function and up-regulates
cardiac gene expression [34, 39], we hypothesized that the
hydrodynamic environment imposed by an intermittent agita-
tion composed of repeated and brief stops could provide cyclic
mechanical forces to the cells and consequently potentiate
iPSC differentiation towards contractile CMs.
Our results show that an intermittent agitation profile with-
out direction change led to a faster cell growth, higher cell
number and enhanced CM differentiation when compared to
the other agitation profiles evaluated (Fig. 3, Table 1). At day
9, an increase of 73.4±7.6 fold in cell number was obtained in
this culture condition (Table 1), reflecting more pronounced
cell proliferation as compared to other two tested conditions.
At this culture time point the percentage of eGFP-positive
cells, as determined by flow cytometry analysis of dissociated
aggregates (Supplementary Methods), was significantly
higher in this culture condition (43.9±6.6 %) than in contin-
uous (23.3±5.0 %, p=0.01) or in intermittent agitation profile
with direction change (16.5±3.7 %, p=0.01) cultures (Ta-
ble 1), suggesting enhanced cardiac differentiation efficiency.
In accordance, lower cell death during antibiotic treatment, as
indicated by a lower accumulation of intracellular LDH in
culture supernatant, was observed (Fig. 3c), indicating that a
higher percentage of puromycin resistant iPSC-derived CMs
and a lower amount of contaminating cells were present in
culture. At the end of the process higher CM number (128.1±
3.3×106 CMs/bioreactor), yield (44.0±2.1 CMs/input iPSC)
and purity (97.4±0.4 %) were obtained in cultures operated
under intermittent agitation without direction change (Fig. 3d,
Table 1); in comparison to continuous agitation and intermit-
tent agitation with direction change profiles, this culture con-
dition enabled a significant improvement of 4- and 6.5-fold in
CM production, respectively (p=0.0001, Table 1).
RT-PCR analyses of RNA isolated from intermittent agita-
tion profile without direction change and continuous agitation
cultures reflect the impact of cyclic mechanical forces pro-
moted by the different hydrodynamic environments on cell
phenotype (Fig. 3e–f). A typical cardiac lineage gene expres-
sion pattern was observed in both culture conditions. The
expression of the pluripotency marker Oct4 progressively
decreased over the course of differentiation reaching very
low levels by day 9 (Fig. 3e–f) and being undetectable at
day 16 purified CMs (Fig. 3e). Additionally, the expression
of the early mesoderm marker T brachyury was up-regulated
from day 4 to day 6 and down-regulated thereafter. These
results allow us to assume that the marked proliferation ob-
served up to day 7 (Fig. 3b) in these cultures might have
resulted from the prevalence of highly proliferative undiffer-
entiated and mesodermal cells up to this timepoint. After-
wards, a progressive increase in the expression of cardiac-
progenitor and cardiac-specific gene markers (Nkx2.5, cTnT,
HCN4, Myl2 and Myl7) was observed. The higher band
intensities at day 9 of differentiation (before initiation of CM
selection) indicated that the majority of the cardiac-specific
markers were greater expressed in cells cultured under inter-
mittent agitation conditions. RT-qPCR analyses further con-
firmed that the expression of the cardiac genes Nkx2.5, cTnT
and Myl7 in cells at this time point was, respectively, 1.4-
(p<0.01), 1.8- (p<0.01) and 1.6-fold (p<0.05) higher in cul-
tures with intermittent agitation than in those with continuous
agitation profile (Fig. 3f). In order to further assess the purity
of puromycin-selected CM preparations, we monitored the
expression of the endodermal marker α-fetoprotein (AFP) in
cells from both cultures. AFP transcripts were detected on
days 6–12 in cell aggregates from both conditions but their
expression was higher in cultures with continuous agitation
profile. On day 12, the expression of AFPwas still observed in
these cultures but not in cultures operated under intermittent
agitation profile without direction change, thus suggesting that
this agitation profile may provide a favorable hydrodynamic
environment for cardiac but not endodermal lineage differen-
tiation. Nonetheless, in both culture conditions the expression
of AFP was not detectable at the end of the selection process
(day 16), confirming the final purity of antibiotic selected
CMs (Fig. 3e). Altogether, these results indicate that the
mechanical stimulus provided to the cells by the agitation
profile inherent to stirred-tank bioreactors can be modulated
to enhance cardiomyogenesis.
CM Differentiation of iPSCs in WAVE Bioreactors
In order to further explore the beneficial impact of mechanical
forces induced by bioreactor hydrodynamics on CM differen-
tiation, we evaluated the capacity of iPSCs to differentiate
towards CMs in WAVE bioreactors.
Cell aggregation was initiated by inoculating single iPSCs
into WAVE bioreactors. After 2 days of cultivation under
hypoxic conditions aggregates presented a size of 167±
43 μm, similar to those obtained in Erlenmeyer flasks (Sup-
plementary Fig. I).
The comparison of CM differentiation efficiency in WAVE
and optimized stirred tank bioreactors (operated under 4 % O2
tension and intermittent agitation without direction change)
revealed that WAVE bioreactor cultures favored CM lineage
commitment, enabling a reduction in the differentiation time
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and increased CM yields (Fig. 4). In these cultures, eGFP-
positive cells and contracting areas in aggregates were
observed from day 5 onwards, increasing rapidly in
number and size (Fig. 4a–c, Supplementary Movie I).
By day 7, 54.3±5.2 % of the aggregates exhibited a
considerable area of eGFP-positive and spontaneously
beating cells (Fig. 4a–b). In accordance with this result,
flow cytometry analyses indicated that 38.6±6.0 % of the
cells in aggregates were eGFP-positive, compared to less
than 5 % detected in stirred tank bioreactors at this time
Fig. 3 Impact of the agitation profile on CM differentiation of iPSCs in
stirred tank bioreactors. Aggregates were inoculated at day 2 in stirred tank
bioreactors operating in continuous and intermittent stirring with or without
change of direction. a. Phase contrast and fluorescence images showing
cell aggregates with eGFP-positive cells (green) at days 9, 12 and 16 of
culture. Scale bars: 200 μm. b–c. Profile of total cell number (b) and
cumulative values of specific rates of LDH release (c) in each bioreactor
condition during culture time. d. Total number of CMs produced in each
bioreactor run (black bars) and CM yields (striped bars). e. Semiquantita-
tive RT-PCR analyses demonstrating the expression of pluripotency (Oct4),
endoderm (AFP), early mesoderm (T-Brachyury) and CM-specific
(Nkx2.5, cTNT, HCN4,Myl2,Myl7) genes in differentiating cells cultured
in bioreactors operating in continuous agitation (left panel) and intermittent
agitation without change of direction (right panel) profiles at different time
points. f. Quantitative RT-PCR analysis showing the relative expression of
Oct4, Nkx2.5, cTnT and Myl7 at day 9. Values were normalized to the
continuous agitation culture condition, except Oct4 expression that was
normalized to RNA from undifferentiated cells (day 0, black bar). Data are
shown as mean±SD of 3 individual bioreactor experiments. Significantly
different, P<0.05 (*) and P<0.01 (**)
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point (Fig. 4c). Importantly, on day 9 of culture, i.e.
before CM selection, the percentage of eGFP-positive
cells among all cells dissociated from aggregates was
almost 2-fold higher in WAVE bioreactors (76.0±5.8 %)
compared to stirred tank cultures (43.9±6.6, Fig. 4c,
Table 1). Consequently, only 2 days of antibiotic treat-
ment were sufficient to obtain a 97.6 % pure CM popu-
lation in WAVE bioreactors (Fig. 4c, Table I). In contrast,
at day 11 of differentiation, aggregates in stirred tank
bioreactors were not yet completely pure and additional
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5 days of antibiotic treatment were required to generate a
97.4 % pure CM population (Fig. 4a, c). In terms of CM
productivities, in optimized stirred tank cultures approxi-
mately 0.430 L medium throughput (total volume of me-
dium used during the process) resulted in the generation
of 0.1x109 CMs, which correspond to a coefficient of
0.2x109 CMs/L. On the other hand, in WAVE bioreactor
2.3x109 CMs were produced in 1.5 L medium throughput
(1 L until day 9, 0.5 L medium exchange at day 9)
obtaining 1.5x109 CMs/L (Table 1). Overall, iPSC differ-
entiation in WAVE bioreactors resulted in an improvement
of about 40 % in CM yield (60.8±0.7 CMs/input iPSC)
and in a 5 times higher CM production per liter of culture
medium throughput (CMs/L) in comparison to optimized
stirred tank cultures (Fig. 4d, Table 1).
RT-PCR analysis showed that early mesoderm, cardiac
progenitor and cardiac-specific genes were expressed ear-
lier and to a higher extent in aggregates from WAVE
cultures than in stirred cultures (Fig. 4e compare to
Fig. 3e). The expression of the pluripotency gene Oct4
decreased more rapidly in aggregates cultured in WAVE
bioreactors reaching very low levels on day 6 of differ-
entiation and undetectable levels from day 8–9 onwards
(Fig. 4e–f). In contrast, the Oct4 transcripts were still
expressed at this stage of differentiation in stirred cultures
and were not detectable only in purified CMs (Figs. 3e,
4f). Additionally, in WAVE cultures the peak in the early
mesodermal gene expression (assayed by the expression
of T-Brachyury) occurred earlier (day 4, Fig. 4e) than in
stirred tank cultures (day 6, Fig. 3e). By day 6, the cardiac
mesodermal (PDGFRα) and cardiac progenitor (cKit and
Nkx2.5) genes were significantly higher expressed in
WAVE than in stirred tank bioreactor cultures. The
expression of cardiac specific markers was also detected
earlier in WAVE cultures and increased gradually in later
stages of differentiation (Fig. 4e). Importantly, the greater
band intensities of cardiac transcripts Nkx2.5, cTnT and
Myl7 observed in WAVE cultures before antibiotic selec-
tion (day 9) indicate that these cultures contained a sub-
stantially higher proportion of CMs than stirred bioreactor
cultures (Figs. 3e, 4e). RT-qPCR analyses confirmed that
by day 9 of differentiation the expression of these three
cardiac markers was significantly higher (1.3, 1.6 and 1.6-
fold, respectively) in WAVE cultures than in stirred tank
bioreactors (Fig. 4f). At the end of antibiotic selection, the
expression of cTnT and Myl7 were very similar in both
bioprocesses (Fig. 4f) confirming the similar degree of
CM purity in both groups (Table 1).
Phase-contrast and scanning-electron microscopy
(SEM) analysis of aggregates on day 9 of differentiation
(i.e. before cell lineage selection) revealed that aggregates
from WAVE and stirred tank bioreactor cultures differed
in size and morphology (Fig. 5a–b, Supplementary
Table I/Fig. III). The mean size of aggregates cultured in
WAVE bioreactors was higher (440.04±107.89 μm) and
they were less spherical and more elongated than aggre-
gates from stirred tank bioreactors (384.41±124.80 μm)
(Supplementary Table I, Supplementary Fig. III). This
higher size and reduced “sphericity” observed in the ag-
gregates cultured in the WAVE bioreactor might be justi-
fied by the different hydrodynamic environment promoted
by this type of bioreactor. Additionally, aggregates from
WAVE bioreactors showed a smooth outer surface
(Fig. 5b), whereas aggregates from stirred tank cultures
exhibited a looser texture and a rough surface in which
cell-cell contacts could be discerned at a higher magnifi-
cation (Fig. 5a). Previous studies demonstrated that during
cardiac differentiation of ESCs, the extracellular matrix
(ECM) mainly composed of collagen type I is deposited
on the surface of differentiating aggregates providing for a
smoother aggregate surface topography [27, 42]. Thus,
our findings may suggest that prior to CM selection the
aggregates cultured in WAVE bioreactors present a higher
deposition of extracellular matrix (ECM) than stirred tank
aggregates. To further confirm these observations, we
stained the whole-mount day 9 aggregates with collagen
type I antibody to determine the amount and distribution
of this ECM component by confocal microscopy. This
analysis clearly revealed that aggregates from WAVE bio-
reactors contain considerably higher levels of collagen
type I than aggregates from stirred tank bioreactors
(Fig. 5c, left panel) and that, based on the fraction of
eGFP-positive cells in whole aggregates, the WAVE ag-
gregates presented higher CM purity than the aggregates
derived in stirred tank bioreactors, before induction of
CM selection. Moreover, at this timepoint a lower
Fig. 4 Differentiation of iPSC into CMs in WAVE and stirred tank
bioreactors. WAVE cultures were compared with optimized stirred tank
bioreactor cultures (operated under 4 % O2 and intermittent agitation
without direction change) in terms of CM differentiation efficiency. a.
Phase contrast and fluorescence images showing cell aggregates
composed by eGFP-positive cells (green) at days 5, 7, 9 and 11. Scale
bars: 200 μm. c. Percentage of eGFP-positive aggregates during culture
time. c. Percentage of eGFP-positive cells during culture time determined
by flow cytometry. d. CM yields (stripped bars) and number of CMs
generated per liter of culture medium throughput (CMs/L, black bars). e.
Semiquantitative RT-PCR analyses showing expression of pluripotency
(Oct4), endoderm (AFP), mesoderm (T-Bra) and CM-specific (Nkx2.5,
cTnT, HCN4,Myl2,Myl7) genes during the time course of differentiation
process in WAVE bioreactors. f. Quantitative RT-PCR analysis of cells
cultured in optimized stirred tank andWAVE bioreactors, at day 6, before
(day 9) and after CM selection (day 16 and 11 for stirred tank andWAVE
bioreactor cultures, respectively). Expression was normalized to RNA
from stirred tank bioreactor cultures operating with intermittent agitation,
except for Oct4 expression that was normalized to RNA of
undifferentiated cells (day 0, black bars). Data are given as mean±SD
of 3 individual bioreactors experiments. Significantly different, P<0.05
(*) and P<0.01 (**)
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percentage of proliferative cells (Ki-67 positive cells) was
observed in aggregates derived from WAVE bioreactors
when comparing with aggregates from stirred tank biore-
actor cultures (approximately 20 % vs. 58 % of the cells,
respectively, Fig. 5c). Taken together, our data show that
iPSCs differentiate into CMs in WAVE bioreactors with
faster kinetics and higher efficiency than in stirred tank
bioreactors. At the end of the differentiation process and
the puromycin selection procedure (day 16 for stirred tank
and day 11 for WAVE bioreactor), collagen type I staining
was similar in intensity and distribution in aggregates
from both types of cultures (Fig. 5c, right panel).
Structural Properties and Action Potential (AP) Parameters
of CMs Generated in Stirred Tank and WAVE Optimized
Bioprocesses
Before CM selection, some aggregates were dissociated into
single cells and seeded in static culture plates for structural
analyses. Immunofluorescence staining for sarcomeric α-
actinin, as well as the distribution of α-MHC protein (eGFP
staining), indicate that cells from WAVE cultures were more
elongated and showed more organized sarcomeric structures,
by day 9, when compared to cells from stirred tank cultures
(Supplementary Fig. IV). These results are in agreement with
the findings of other studies showing that cyclic tensions
promote elongation of the cell membrane, orientation of actin
filaments and a higher structural organization [33, 39].
After the differentiation and selection process, beating
cardiospheres (Supplementary Movie II) were also dis-
sociated into single cells and seeded in 2D plates for
structural and functional characterization. Monolayers of
pure CMs were obtained and cells maintained their
spontaneous beating activity, which became synchro-
nized over culture time (Supplementary Movie III). Im-
munocytochemical analysis of cardiac-specific proteins
α-MHC, sarcomeric α-actinin, titin and troponin I re-
vealed that iPSC derived-CMs produced in both biore-
actor systems stained positive for these cardiac structur-
al proteins (Fig. 6), presenting an organized striated
pattern typical of CMs.
In order to assess the electrophysiological properties of
CMs generated in both bioreactor systems, AP recordings
in single CMs were performed. The great majority of
puromycin selected CMs derived from both bioprocesses
displayed an atrial-like AP morphology (stirred tank:
100 %, WAVE: 92 %). These findings are also in agree-
ment with the enhanced expression of atrial transcripts
Fig. 5 Scanning-electron and confocal microscopy of iPSC-derived cell
aggregates and cardiospheres. a–b. SEM micrograph of differentiating
cell aggregates collected from stirred tank (a) and WAVE (b) bioreactors
at day 9 of differentiation. Higher magnification images evidence the
differences in aggregate surface topography. c. Immunofluorescence and
confocal microscopy images of the whole-mount day 9 aggregates (left
panel) and cardiospheres collected at the end of selection process (right
panel). The frequency and distribution of eGFP-positive (green), Ki-67
(red) and collagen type I-positive cells (red) is shown. Nuclei were
labeled with DAPI (blue). Scale bars: 100 μm
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(Myl7) and reduced expression of the transcripts specific
for the pacemaker (HCN4) and ventricular-like phenotypes
(Myl2) detected in the final differentiated population by
RT-PCR (Figs. 3e and 4e). The AP characteristics of
purified CMs generated in WAVE and stirred cultures
were very similar showing comparable maximum diastolic
potential (MDP), beating frequency, AP upstroke velocity
(Vmax), velocity of diastolic depolarization (Vdd) and AP
duration (APD) (Supplementary Table II). Additionally, the
CMs generated in WAVE and stirred tank bioreactor cul-
tures exhibited AP parameters similar to the ones de-
scribed in literature for atrial-like late stage development
fetal CMs (day 16–19 of differentiation), such as MDP
(−63.3±1.3 mV), frequency (234±19 beats/min), Vmax
(27.9±0.7 V/s) and Vdd (0.115±0.017 V/s) [11]. Besides
exhibiting largely indistinguishable AP properties, CMs
produced in both bioprocesses also responded similarly
to adrenergic and muscarinic agonists, isoproterenol and
carbachol, respectively. When isoproterenol was adminis-
tered to CMs a significant increase of AP frequency and a
shortening of APD at 90 % of repolarization (APD90)
was observed (Fig. 7a). Moreover, positive chronotropic
effects of isoproterenol were reversible upon washout
(Fig. 7b). In contrast, the administration of carbachol, a
synthetic acetylcholine analog, evoked a significant reduc-
tion in the beating rate in CMs from stirred tank and
WAVE bioreactors, which was also reversible upon wash-
out (Fig. 7c–d).
In order to further evaluate the functional integrity of CMs
produced in WAVE bioreactors we performed real-time intra-
cellular calcium imaging with the calcium indicator dye Rhod-
3. This analysis revealed that distinct iPSC-derived CMs from
a beating monolayer present synchronized oscillatory patterns
of intracellular calcium concentrations (Fig. 7e–f). Supple-
mentary Movie IV shows a representative live imaging re-
cording of whole-cell calcium transients for contracting CMs
produced in WAVE bioreactors.
Overall, these results show that CMs produced using the
protocol developed in this work exhibit intact molecular,
structural and functional properties.
Discussion
In this study we developed a new method for mass production
of murine iPSC-derived CMs using environmentally con-
trolled bioreactors. The expansion and CM differentiation of
human and murine pluripotent stem cells in stirred tank bio-
reactors have been reported by our group [22] and others [25,
26, 43]. Aiming to further improve CM yields, we designed a
bioreactor protocol that combine low oxygen concentrations
with a cyclic mechanical rich environment by manipulating
bioreactor hydrodynamics, more specifically the agitation
type and profile. In this study, we showed for the first time
that a DO of 4 % O2 tension, along with the use of either an
Fig. 6 Structural properties of CMs generated in stirred tank and WAVE
optimized bioprocesses. Cardiospheres were dissociated into single cells,
plated on 2D plates and after being cultured for up to 2 weeks, stained for
CM markers. Immunocytochemical analysis of eGFP-positive CMs
(green) using sarcomeric α-actinin, titin and troponin I (red) antibodies.
Nuclei are counterstained with DAPI (blue). Scale bars: 50 μm
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intermittent stirring or a wave-induced agitation, favors iPSC
differentiation towards the CM lineage. Using an intermittent
agitation in stirred tank bioreactors, we were able to improve
by 1000-fold CM yields (up to 44 CMs/input iPSC) when
compared to normoxic continuously agitated cultures. More-
over, we demonstrated that the wave-induced agitation in
combination with 4 % O2 tension from the beginning of iPSC
differentiation increases the kinetics of cardiac differentiation,
enabling a reduction of bioprocess duration by 5 days, and
further improves the CM yields (60 CMs/input iPSC). To our
knowledge, this is the first study reporting the use of theWAVE
bioreactor for PSC culture. This type of bioreactor presents a
simple design, appealing to either biological engineers or med-
ical professionals and offers a low shear environment suitable
for growth of sensitive cells such as stem cells [44].
Oxygen tensions and mechanical cues have been shown to
mediate PSCs proliferation and differentiation. In our study,
we showed that hypoxic exposure (4 % O2 tension) improves
CM differentiation efficiencies by enhancing both cell prolif-
eration and cardiomyogenesis when compared to normoxia
conditions. This data is in accordance with previous studies
[26], reporting that low DO concentrations enhanced the
proliferation of ESCs and the expression of mesodermal, early
and late cardiac-specific genes [26]. It is also established that
CMs actively respond to mechanical cues from the environ-
ment in a frequency-dependent manner and that those cues
can modulate electric remodeling, alterations in gene expres-
sion, autocrine and paracrine effects, and consequently cardiac
tissue organization and development [39]. Cardiac cells expe-
rience mechanical strains with every heartbeat, i.e., at a pul-
satile frequency close to 1 Hz [45]. Aiming to mimic the
physiological environment, previous studies have applied me-
chanical stimulation at frequencies of 1 Hz on commercial or
custom built devices to engineered cardiac tissues [31]. In our
protocol, cells were subjected to distinct mechanical forces by
manipulating the hydrodynamic environment in scalable read-
ily available bioreactor systems. In stirred tank bioreactors,
using an intermittent stirring, mechanical forces at frequencies
close to 0.033 Hz were generated, whereas with a wave-
induced agitation higher frequencies were reached (0.82–
0.86 Hz). Thus, the differences in the temporal gene expres-
sion pattern and cardiac differentiation efficiency observed in
stirred and WAVE cultures may be related to the frequency of
mechanical loading applied in both systems. In accordance
with literature, the effect of mechanical forces on
cardiomyogenic differentiation is highly dependent on the
experimental setup. Several variables including force magni-
tude, frequency, direction, duration of application, and at what
Fig. 7 Functional characterization of CMs produced in stirred tank and
WAVE bioreactors. a–d. Pharmacological response of CMs. Effect of
1 μM Isoproterenol (Iso, a–b) and 1 μM Carbachol (CCh, c–d) on
beating frequency and on action potential (AP) duration at 90 % repolar-
ization (APD90) in iPSC-derived CMs. b, d. Representative recordings of
APs from WAVE bioreactor-derived CMs. APs were recorded before the
application of the drug (Control) in the presence of the drug (Iso/CCh),
and after washout of the drug (washout). e–f. Calcium transients of CMs
produced in WAVE bioreactor. e. Graphical representation of calcium
level cycling, during CMs contraction, determined by confocal imaging
of the cell permeant calcium indicator dye Rhod-3, for three different
cells. f. Pseudo-color images show minimal (Ca2+ min, left image) and
maximal (Ca2+ max, right image) Rhod-3 fluorescence intensity in the
three analyzed cells. Significantly different, P<0.05 (*) and P<0.01 (**)
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stage of differentiation the force is applied, have been shown
to affect cell fate decisions [39, 40, 46]. In fact, these aspects
were noted to also be critical for the success of the protocol
described herein. Our results suggest that an intermittent agi-
tation profile with change of stirring direction is not suitable
for iPSC differentiation into CMs (low CM numbers and
purities were achieved at the end of the differentiation pro-
cess). Also, higher cell lysis was observed during all culture
time, suggesting that this agitation profile may have induced
high shear rate for cells, compromising cell viability, prolifer-
ation capacity and differentiation efficiency. Herein we con-
sidered that the major mechanical stimulus induced to the cells
is the hydrodynamic environment provided by an intermittent
and wave-induced agitation. However, it should be noted that
fluid shear stress per se might also influence cell behavior. The
effect of shear stress on cell pluripotency and cardiomyogenesis
has already been described. For example, mESCs exposed to
laminar shear stress (4 days at 5 dyn/cm2) expressed higher
levels of mesodermal markers [47]. On the other hand, fluid
shear forces promoted by distinct types of impellers, such as
single glass-ball stirring pendulum (1.52 dyn/cm2, 75 rpm)
[48], pitched-blade impellers (2–5.2 dyn/cm2, 50–100 rpm)
[49] and paddled impellers (4.5–7.8 dyn/cm2, 80–120 rpm)
[50] have shown to maintain or increase the expression of
pluripotency markers in PSC cultured in bioreactor systems.
In WAVE bioreactors the mean values of shear stress (0.05 Pa,
0.5 dyn/cm2) in both 2 L and 20 L working volumes [51]) were
considerably lower than the ones indicated above for stirred
bioreactors. In accordance, we observed a 6-times lower fold
increase in the cumulative LDH in WAVE bioreactor cultures,
from day 2 to day 9, when compared to stirred tank bioreactor
cultures (Supplementary Fig. II). These results reflect the re-
duced impact that fluid shear stress has on cell viability in
WAVE bioreactor cultures. Future experiments using Compu-
tational Fluid Dynamics tools should be performed aiming at a
deeper characterization of the hydrodynamic environment and
quantification of the type and magnitude of the stresses gener-
ated in each bioreactor strategy.
It should be pointed out that mechanical forces, besides
promoting elongation of the cell membrane and orientation of
actin filaments [33, 39], regulate ECM synthesis, more spe-
cifically, result in enhanced synthesis of collagen, the most
abundant protein in cardiac tissue [45]. In this study, we
showed that by day 9 of differentiation, cultures that have
experienced higher mechanical loading (WAVE cultures) are
composed of cells with more organized sarcomeric structures,
and aggregates with smoother surface topography due to a
higher deposition of collagen type I.
Aside from different hydrodynamic environments, cells
were cultured at 4 % O2 tension during different periods of
time in these systems (in WAVE bioreactor from day 0 to day
11 and in stirred tank bioreactor from day 2 to day 16).
Therefore, exposing cells to reduced oxygen concentrations
from the beginning of differentiation could also have contrib-
uted to the beneficial effect on CM differentiation observed in
WAVE cultures.
The establishment of pure CM preparations is impera-
tive for future clinical application of these cells. Our
finding that a hypoxic environment along with a wave-
induced agitation enables the production of CMs at a
purity of 76 % in nine days without growth factor- direct-
ed differentiation and without antibiotic selection repre-
sents a major advance towards development of robust and
clinically applicable bioprocesses. To facilitate the opti-
mization of the described method, we have used a trans-
genic murine iPSC line, in which the cardiac-restricted α-
MHC promoter drives the expression of a puromycin
resistance gene and eGFP. Therefore, antibiotic treatment,
after day 9, resulted in the generation of an essentially
pure CM population. In WAVE bioreactors, only two days
were sufficient to achieve 97 % CM purity by puromycin
selection whereas in stirred tank cultures 7 days of selec-
tion were needed to reach the same purity. CMs generated
at faster kinetics may have higher therapeutic potential in
their in vivo applications. Namely, Boheler and coworkers
showed that ESC-derived CMs isolated at day 11 of
differentiation, in contrast to cells obtained at day 16–18
of differentiation, were more resistant to hypoxia in vitro
and survived longer following injection into healthy
hearts of athymic nude mice [52]. These data suggest that
early-stage CMs may have greater potential to engraft and
improve the myocardial contractile function following
infarction. Therefore, it is appealing to hypothesize that
day 11 CMs obtained in WAVE bioreactors may exhibit
higher survival and engraftment potential after
intramyocardial transplantation than day 16 CMs generat-
ed in stirred tank bioreactors. In order to increase the
safety of the final CM preparation, non-genetic cell-
lineage purification protocols should be considered. Pro-
cedures involving density-gradient centrifugation [53], the
use of a mitochondrial dye [54] or antibodies targeting
cardiac-specific surface markers [55–57] have been
established for CM enrichment and can be combined with
the developed bioprocess. However, these methods are
either labor intensive or expensive which limit their scal-
ability. Non-genetic CM lineage purification strategies
based on distinct metabolic requirements of CMs and
non-CM cell types have been described. For example, it
has been shown that CMs survive in serum-free medium
[58, 59] or in glucose-depleted culture medium containing
lactate [18], while other cell types do not. In addition,
selective elimination of remaining contaminating pluripo-
tent cells could be achieved by treatment of final CM
preparations with small molecules that do not compromise
CM viability and functionality but are toxic to PSCs [60].
From a large-scale production perspective this type of
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approaches are more appealing and could be easily incor-
porated in our bioreactor protocol aiming at establishing a
clinically scalable and cost-effective integrated bioprocess
for CM differentiation and purification.
Another major requirement for the biomanufacturing of
stem cell derivatives is to ensure that the final product fulfills
the desired quality requisites for biomedical applications in-
cluding phenotype, potency and functionality [21]. Here, we
showed that CMs obtained in both bioreactor systems pre-
sented typical cardiac morphology, electrophysiology, hor-
monal response to β-adrenergic and muscarinic receptor stim-
ulation and rhythmic intracellular calcium transients. The
most predominant CM subtype observed in both bioprocesses
was the atrial-like phenotype, which was largely influenced by
the type of cardiac specific promoter that was driving the
expression of antibiotic resistance gene in our genetically
engineered cells. The α-MHC promoter is active mostly in
atrial regions during embryonic and early fetal development
[61], therefore it seems that the selection strategy used in this
work is favoring the production of immature fetal-like cells
that present action potentials resembling those found in atrial
cells and that have not yet assumed more recognizable cardiac
chamber subtypes. Future efforts should be directed towards
improving the electrophysiological maturity of the produced
CMs and enhancing cardiac subtype specification, for exam-
ple by extending the time in culture after the selection process.
In conclusion, this study describes a robust and scalable
protocol for differentiation of murine iPSC into CMs in con-
trolled hypoxic and mechanical environment. In this work we
have focused on murine iPSC as a model system for
bioprocess development, and on a simple non-directed differ-
entiation protocol to clearly identify the impact of each culture
condition tested on CM differentiation. Although human and
mouse PSC lines utilize overlapping developmental path-
ways, much optimization is required when translating proto-
cols between species. We are aware that further optimization
to our protocol will be required when translating to human
PSCs. For example the use of chemically defined and serum-
free media supplemented with cytokines will be of major
importance. Nevertheless, it is our conviction that the biore-
actor protocol herein described (i.e. the controlled hypoxic
and specific hydrodynamic environment promoted by an in-
termittent stirring or a wave induced agitation) will be able to
further improve the protocols already reported for human PSC
differentiation towards CMs by enhancing culture homogene-
ity, process reproducibility, CM yields and productivities. It is
widely known that the use of chemically defined media and
growth-factor supplements considerably increases the cost of
the differentiation process. Thus, the development of cost-
effective bioprocesses is also highly dependent on increasing
the number of CMs generated per liter of culture medium
throughput (CMs/L). Here, by controlling key environmental
conditions in cardiac development, we were able to produce
up to 1.6x109 CMs/L in a single WAVE 11-days bioreactor
run. To our knowledge this is the highest value that has been
reported to date [43]. Hopefully, our achievements will also
contribute for the development of affordable bioprocesses for
mass production of human PSC-derived CMs, by reducing the
need/amount of expensive cytokine inductive cocktails and/or
the cardiac differentiation protocol duration.
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